Life Sciences Insurance Explained in 5 Minutes

Business Insurance
4 followers
#LifeSciencesInsurance #BiotechInsurance #DirectorsAndOfficers
Life sciences insurance is not the same as business insurance, and most biotech and medical device founders don't find that out until a board member, CRO contract, or investor deadline puts their close on hold. This video covers the five insurance gaps that catch life science founders off guard before Series A, and what to do about each one.
AI Generated·May contain errors
Video Summary
AI GeneratedGordon Coyle explains five critical insurance gaps that often blindside life science and biotech founders. He emphasizes that because these companies have unique risk profiles, they require specialized insurance strategies to avoid delaying funding rounds, stalling clinical trials, or exposing leadership to personal liability.
You're two weeks from closing your seed round. Your lead investor term sheet is signed. Your
science is solid. And then one of your incoming board members calls and asks one question.
Where's your DNO policy? You don't have one. You didn't know you needed one. And now your
close is on hold until you can prove to a board member that they won't be personally liable for
sitting on your board. This happens all the time. And it's just the first of five insurance
surprises that Catch Life Science founders completely off guard. In this video, I'm going
to walk you through the five gaps that I see trip up biotech founders before they ever get to
Series A and what to do about each one of them before it becomes an emergency. I am Gordon Coyle.
For over 40 years, I've worked with startup, early stage firms, and up to seven, eight, and nine
figure business owners, helping them navigate the complex world of business insurance. I have seen
every problem and costly mistake you can imagine. Here, I share the insider strategies and real
world solutions that protect your business and save you money. Here's the reality. If you're
building a biotech medical device company, diagnostics platform, or a digital health
product, you are not a normal business. Your risk profile looks nothing like a tech startup or a
services company. And most founders don't figure that out until something goes sideways. So the
number one issue that we see is that DNO is not a post-revenue decision. Directors and Officers
Liability Insurance, or DNO, protects your leadership team personally for the decisions
they make on behalf of your company. The moment you take outside investment, you need it. Not
because something bad happened, but because no experienced board member will serve on your
company's board without it. No sophisticated investor will close without it. This isn't about
claims. It's about credibility. If you're raising capital and you don't have DNO in place, you're
signaling that you don't understand the basics of corporate governance. Get it before you need it,
because by the time you need it, you're already behind the eight ball.
Fact number two, this is not normal insurance and most brokers can't place it. Life science
insurance is a specialized market. There are only a handful of insurers in the country who actually
underwrite clinical trial liability, early stage biotech product liability, and the specific
endorsements your partners are going to demand. Your general liability policy, well, that excludes
clinical trials entirely. It excludes most of the product specific exposures you're going to face.
A generalist broker who mostly writes contractors and office tenants isn't going to know how to find
the carriers who do this work, let alone structure the program correctly. This is a market where the
wrong broker doesn't just cost you money, they cost you time. In life sciences, time is the
number one thing you can't afford to waste. Number three, your CRO contract will stall
if your insurance isn't built for it. This dovetails directly with what I said. When you
sign with a CRO, a CDMO, or a hospital partner for clinical trials, their contract has an insurance
specific exhibit. It will require specific limits, specific endorsements, additional insured status,
primary and non-contributory language, waiver of subrogation. If your broker has never seen
one of these exhibits before, you're looking at weeks of delays while they figure it out what it
means and scramble to find an insurer who can provide it. I've seen deals held up for a month
because the insurance language wasn't right. That's a month of clinical timeline you don't
get back. Number four, cyber insurance is not optional when you're holding patent data. Most
early stage founders think cyber insurance is something they'll deal with later, but you're
sitting on two of the most sensitive categories of data that exists, patient health information
and proprietary research. That's a dual exposure. A breach doesn't just trigger a HIPAA obligation,
it puts your intellectual property at risk. And running any kind of digital health platform or
collecting clinical trial data, the regulatory exposure compounds that fast. This isn't a
$5,000 afterthought, it's a core part of your insurance stack from day one. Number five,
your insurance program needs to scale with your milestones, not react to them. This is the one
that separates companies that handle insurance well from companies that are constantly scrambling.
Every major milestone changes your insurance needs. Filing your IND or IDE application,
enrolling your first trial participants, getting FDA clearance, signing your first distribution
agreement. Each one of these events shifts your risk profile and changes what your program needs
to look like. If you're waiting until the milestone hits to figure out the insurance,
you're already too late. The companies that do this well build their insurance program with the
next 12 to 18 months of milestones in mind. So when the moment arrives, they're ready, not
scrambling. Look, if you're building a life sciences company, here's what I want you to
take away. Insurance in this space is not something you figure out at the last minute.
It's not something that you hand to a generalist broker who's going to Google their way through it.
It's a specialized market that requires specialized knowledge and the cost of getting it wrong is
measured in delayed deals, exposed board members, and gaps that show up at the worst possible time.
Whether you're researching insurance for your life sciences company for the first time or you
already have coverage and you're starting to realize it wasn't built for where you're headed,
that's exactly the kind of conversation I have almost every day. Let's have a conversation,
30 minutes, no pressure, no obligation, just an honest look at where you stand and whether
your program can keep up with your next milestone. There's a link in the description box below,
hit it, and let's set up some time to talk. Thanks.
